- Investing Ideas
- Pakistani Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Pakistani Pharmaceuticals & Biotech Undervalued over 20% based on DCF
Results
2
0 new
Companies which are undervalued more than 20% based on the Discounted Cash Flow valuation.
2 companies
GlaxoSmithKline Pakistan
Market Cap: PK₨113.9b
A biopharma company, engages in the discovery, development, and delivery of medicines and vaccines in Pakistan.
GLAXO
PK₨357.75
7D
-4.1%
1Y
-8.8%
Abbott Laboratories (Pakistan)
Market Cap: PK₨93.1b
Manufactures, imports, and markets generic pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products in Pakistan, Afghanistan, Sri Lanka, Bangladesh, and Switzerland.
ABOT
PK₨951.11
7D
-1.3%
1Y
-12.9%